Identification

Name
Mepivacaine
Accession Number
DB00961  (APRD01094)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)

Structure
Thumb
Synonyms
  • (+-)-1-Methyl-2',6'-pipecoloxylidide
  • 1-methyl-2',6'-pipecoloxylidide
  • DL-Mepivacaine
  • Mepivacaina
  • Mepivacainum
  • N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide
  • N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide
Product Ingredients
IngredientUNIICASInChI Key
Mepivacaine Hydrochloride4VFX2L7EM51722-62-9RETIMRUQNCDCQB-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
3% Polocaine DentalLiquid30 mgInfiltrationDentsply Pharmaceutical2009-10-19Not applicableCanada
CarbocaineInjection, solution20 mg/mLInfiltrationHospira, Inc.1960-03-15Not applicableUs
CarbocaineInjection, solution10 mg/mLInfiltrationHospira, Inc.1960-03-15Not applicableUs
CarbocaineInjection, solution20 mg/mLEpidural; InfiltrationHospira, Inc.1960-03-15Not applicableUs
CarbocaineInjection, solution10 mg/mLEpidural; InfiltrationHospira, Inc.1960-03-15Not applicableUs
CarbocaineInjection, solution15 mg/mLEpidural; InfiltrationHospira, Inc.1960-03-15Not applicableUs
Carbocaine Liq 2%Liquid20 mgEpidural; IntracaudalSanofi1959-12-312001-08-10Canada
Carbocaine 1%Solution1 %InfiltrationPfizer2001-07-15Not applicableCanada
Carbocaine 1%Solution1 %Epidural; IntracaudalPfizer2001-06-01Not applicableCanada
Carbocaine 2%Solution20 mgEpidural; IntracaudalPfizer2001-07-15Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarbocaineInjection, solution30 mg/mLSubcutaneousCaresteam Health, Inc.2011-01-01Not applicableUs
IQ Dental MepivacaineInjection, solution30 mg/mLSubcutaneousIq Dental2012-08-15Not applicableUs
IsocaineInjection, solution30 mg/mLSubcutaneousNovocol Inc.2010-08-20Not applicableUs
MepivacaineInjection, solution30 mg/mLSubcutaneousPatterson Dental2011-01-01Not applicableUs
MepivacaineInjection, solution30 mg/mLSubcutaneousDarby Dental Supply Llc2011-01-14Not applicableUs
MepivacaineInjection, solution30 mg/mLSubcutaneousNovocol Inc.2013-07-31Not applicableUs
MepivacaineInjection, solution30 mg/mLSubcutaneousBenco Dental2011-01-01Not applicableUs
MepivacaineInjection, solution30 mg/mLSubcutaneousNDC, Inc.2015-04-10Not applicableUs
Mepivacaine HydrochlorideInjection, solution30 mg/mLDental; InfiltrationHospira, Inc.2008-04-282017-02-23Us
Mepivacaine HydrochlorideInjection, solution30 mg/mLSubcutaneousHenry Schein2011-01-01Not applicableUs
International/Other Brands
Carbocaine / Scandicaine
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
2% Polocaine Dental With Levonordefrin 1:20,000Mepivacaine Hydrochloride (20 mg) + Levonordefrin (0.05 mg)SolutionInfiltrationDentsply Pharmaceutical1990-12-312011-08-04Canada
Carbocaine 2% With Neo-cobefrinMepivacaine Hydrochloride (20 mg) + Levonordefrin (0.05 mg)SolutionInfiltrationKodak Canada Inc.2005-04-222008-07-14Canada
Carbocaine 2% With Neo-cobefrinMepivacaine Hydrochloride (20 mg) + Levonordefrin (50 mcg)SolutionInfiltrationCarestream Health Inc.2006-09-01Not applicableCanada
Carbocaine with Neo-CobefrinMepivacaine Hydrochloride (20 mg/mL) + Levonordefrin (.05 mg/mL)Injection, solutionSubcutaneousCaresteam Health, Inc.2011-01-01Not applicableUs
Isocaine HCl Inj 2%Mepivacaine Hydrochloride (20 mg) + Levonordefrin (50 mcg)SolutionInfiltrationNovocol Inc.1977-12-31Not applicableCanada
Leep RediKitMepivacaine Hydrochloride + Epinephrine bitartrate + Ferric subsulfate + Iodine + Lidocaine hydrochloride + Potassium IodideKitCooper Surgical, Inc.2015-05-31Not applicableUs
Mepivacaine Hydrochloride and LevonordefrinMepivacaine Hydrochloride (20 mg/mL) + Levonordefrin (.05 mg/mL)Injection, solutionSubcutaneousDarby Dental Supply Llc2011-01-14Not applicableUs
Mepivacaine Hydrochloride with LevonordefrinMepivacaine Hydrochloride (20 mg/mL) + Levonordefrin (.05 mg/mL)Injection, solutionSubcutaneousHenry Schein2011-01-01Not applicableUs
Mepivacaine With LevonordefrinMepivacaine Hydrochloride (20 mg/mL) + Levonordefrin (.05 mg/mL)Injection, solutionSubcutaneousBenco Dental2011-01-01Not applicableUs
Mepivacaine with levonordefrinMepivacaine Hydrochloride (20 mg/mL) + Levonordefrin (.05 mg/mL)Injection, solutionSubcutaneousPatterson Dental2011-01-01Not applicableUs
Categories
UNII
B6E06QE59J
CAS number
96-88-8
Weight
Average: 246.348
Monoisotopic: 246.173213336
Chemical Formula
C15H22N2O
InChI Key
INWLQCZOYSRPNW-UHFFFAOYSA-N
InChI
InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)
IUPAC Name
N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide
SMILES
CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C

Pharmacology

Indication

For production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.

Structured Indications
Not Available
Pharmacodynamics

Mepivicaine is a local anesthetic of the amide type. Mepivicaine as a reasonably rapid onset and medium duration and is known by the proprietary names as Carbocaine and Polocaine. Mepivicaine is used in local infiltration and regional anesthesia. Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal.

Mechanism of action

Local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: pain, temperature, touch, proprioception, and skeletal muscle tone.

TargetActionsOrganism
ASodium channel protein type 10 subunit alpha
inhibitor
Human
Absorption

Absorbed locally. The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution.

Volume of distribution
Not Available
Protein binding

Mepivacaine is approximately 75% bound to plasma proteins. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma.

Metabolism

Rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine. The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.

Route of elimination

It is rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine.The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.

Half life

The half-life of mepivacaine in adults is 1.9 to 3.2 hours and in neonates 8.7 to 9 hours.

Clearance
Not Available
Toxicity

The mean seizure dosage of mepivacaine in rhesus monkeys was found to be 18.8 mg/kg with mean arterial plasma concentration of 24.4 µg/mL. The intravenous and subcutaneous LD 50 in mice is 23 mg/kg to 35 mg/kg and 280 mg/kg respectively.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Mepivacaine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with 7-Nitroindazole.Experimental
AcebutololThe serum concentration of Mepivacaine can be increased when it is combined with Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mepivacaine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Mepivacaine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Mepivacaine can be increased when it is combined with Alprenolol.Approved, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Mepivacaine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Mepivacaine.Approved, Investigational
ArotinololThe serum concentration of Mepivacaine can be increased when it is combined with Arotinolol.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Mepivacaine.Approved
AtenololThe serum concentration of Mepivacaine can be increased when it is combined with Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Azaperone.Investigational, Vet Approved
AzelastineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Barbital.Illicit
BefunololThe serum concentration of Mepivacaine can be increased when it is combined with Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Benzyl alcohol.Approved
BetaxololThe serum concentration of Mepivacaine can be increased when it is combined with Betaxolol.Approved
BevantololThe serum concentration of Mepivacaine can be increased when it is combined with Bevantolol.Approved
BisoprololThe serum concentration of Mepivacaine can be increased when it is combined with Bisoprolol.Approved
BopindololThe serum concentration of Mepivacaine can be increased when it is combined with Bopindolol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Mepivacaine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Mepivacaine can be increased when it is combined with Bucindolol.Investigational
BufuralolThe serum concentration of Mepivacaine can be increased when it is combined with Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Mepivacaine.Approved, Investigational
BupranololThe serum concentration of Mepivacaine can be increased when it is combined with Bupranolol.Approved
BuprenorphineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Mepivacaine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Mepivacaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mepivacaine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mepivacaine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carisoprodol.Approved
CarteololThe serum concentration of Mepivacaine can be increased when it is combined with Carteolol.Approved
CarvedilolThe serum concentration of Mepivacaine can be increased when it is combined with Carvedilol.Approved, Investigational
CeliprololThe serum concentration of Mepivacaine can be increased when it is combined with Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mepivacaine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Mepivacaine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Mepivacaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clopenthixol.Experimental
CloranololThe serum concentration of Mepivacaine can be increased when it is combined with Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mepivacaine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Mepivacaine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Mepivacaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Mepivacaine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mepivacaine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mepivacaine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Mepivacaine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mepivacaine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mepivacaine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Mepivacaine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mepivacaine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mepivacaine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mepivacaine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Mepivacaine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mepivacaine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Mepivacaine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Entacapone.Approved, Investigational
EpanololThe serum concentration of Mepivacaine can be increased when it is combined with Epanolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Escitalopram.Approved, Investigational
EsmololThe serum concentration of Mepivacaine can be increased when it is combined with Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Mepivacaine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Mepivacaine.Approved
EthanolMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mepivacaine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Mepivacaine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mepivacaine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mepivacaine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mepivacaine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Mepivacaine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Mepivacaine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Mepivacaine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Mepivacaine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Mepivacaine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Mepivacaine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Hexobarbital.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Mepivacaine.Approved, Investigational
HydrocodoneMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mepivacaine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Indalpine.Investigational, Withdrawn
IndenololThe serum concentration of Mepivacaine can be increased when it is combined with Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Mepivacaine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Mepivacaine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketobemidone.Approved, Investigational
LabetalolThe serum concentration of Mepivacaine can be increased when it is combined with Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lamotrigine.Approved, Investigational
LandiololThe serum concentration of Mepivacaine can be increased when it is combined with Landiolol.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levetiracetam.Approved, Investigational
LevobunololThe serum concentration of Mepivacaine can be increased when it is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mepivacaine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Mepivacaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Mepivacaine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Mepivacaine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Mepivacaine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Melperone.Approved, Investigational
MepindololThe serum concentration of Mepivacaine can be increased when it is combined with Mepindolol.Experimental
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mepivacaine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Mepivacaine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Mepivacaine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Mepivacaine.Approved
MethotrimeprazineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Mepivacaine.Approved
MetipranololThe serum concentration of Mepivacaine can be increased when it is combined with Metipranolol.Approved
MetoprololThe serum concentration of Mepivacaine can be increased when it is combined with Metoprolol.Approved, Investigational
MetyrosineMepivacaine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Mepivacaine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Investigational
MirtazapineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Mepivacaine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Investigational
NadololThe serum concentration of Mepivacaine can be increased when it is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mepivacaine.Approved
NebivololThe serum concentration of Mepivacaine can be increased when it is combined with Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Mepivacaine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Mepivacaine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Mepivacaine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Mepivacaine.Approved
OpiumThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Opium.Approved, Illicit
OrphenadrineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Mepivacaine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Oxethazaine.Approved, Investigational
OxprenololThe serum concentration of Mepivacaine can be increased when it is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Mepivacaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mepivacaine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mepivacaine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Mepivacaine.Approved
ParaldehydeMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Paroxetine.Approved, Investigational
PenbutololThe serum concentration of Mepivacaine can be increased when it is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mepivacaine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Mepivacaine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Mepivacaine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mepivacaine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mepivacaine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Mepivacaine.Approved
PindololThe serum concentration of Mepivacaine can be increased when it is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Mepivacaine can be increased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pomalidomide.Approved
PractololThe serum concentration of Mepivacaine can be increased when it is combined with Practolol.Approved
PramipexoleMepivacaine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Mepivacaine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Mepivacaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Mepivacaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mepivacaine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Mepivacaine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Mepivacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Mepivacaine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Mepivacaine can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Mepivacaine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Mepivacaine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Mepivacaine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mepivacaine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mepivacaine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mepivacaine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Mepivacaine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Romifidine.Vet Approved
RopiniroleMepivacaine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Mepivacaine.Approved
RotigotineMepivacaine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Mepivacaine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mepivacaine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Mepivacaine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved
SotalolThe serum concentration of Mepivacaine can be increased when it is combined with Sotalol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mepivacaine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Mepivacaine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sultopride.Experimental
SuvorexantMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TalinololThe serum concentration of Mepivacaine can be increased when it is combined with Talinolol.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptMepivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Mepivacaine.Approved
TertatololThe serum concentration of Mepivacaine can be increased when it is combined with Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetrodotoxin.Investigational
ThalidomideMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Mepivacaine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Mepivacaine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Mepivacaine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tilidine.Experimental
TimololThe serum concentration of Mepivacaine can be increased when it is combined with Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mepivacaine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mepivacaine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Mepivacaine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Mepivacaine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mepivacaine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mepivacaine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Mepivacaine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Mepivacaine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Mepivacaine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zolazepam.Vet Approved
ZolpidemMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Mepivacaine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Mepivacaine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US2799679
General References
Not Available
External Links
Human Metabolome Database
HMDB15096
KEGG Compound
C07528
PubChem Compound
4062
PubChem Substance
46507857
ChemSpider
3922
BindingDB
50417964
ChEBI
6759
ChEMBL
CHEMBL1087
Therapeutic Targets Database
DAP001232
PharmGKB
PA164748741
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Mepivacaine
ATC Codes
N01BB53 — Mepivacaine, combinationsN01BB03 — Mepivacaine
AHFS Codes
  • 72:00.00 — Local Anesthetics
FDA label
Download (180 KB)
MSDS
Download (73.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedHealth Services ResearchLocal Anesthetic Effectiveness1
1, 2CompletedTreatmentIntervertebral Disc Degeneration / Intervertebral Disc Disease / Low Back Pain (LBP)1
3CompletedTreatmentAnesthetics, Local1
3RecruitingTreatmentInsertion of Intrauterine Contraception1
3Unknown StatusTreatmentEmergency / Pain / Traumatic Injuries1
4CompletedTreatmentAmbulatory Surgical Procedures / Arthroplasty, Replacement, Knee / Early Ambulation / Pain Management / Spinal Anaesthesia1
4CompletedTreatmentArthroplasties, Hip Replacement1
4CompletedTreatmentKnee Arthritis1
4CompletedTreatmentOrthopedic Surgical Procedures / Postoperative pain1
4CompletedTreatmentSymptomatic Irreversible Pulpitis1
Not AvailableCompletedNot AvailableImpact of Anesthetic Choice on Costs1
Not AvailableCompletedTreatmentAnaesthesia therapy / Caudal epidural block therapy / Neuromuscular Blockade1
Not AvailableCompletedTreatmentInterscalene Block / Shoulder Arthroscopy1
Not AvailableRecruitingBasic ScienceCancer of Bladder1
Not AvailableRecruitingPreventionArterial Hypotension1
Not AvailableRecruitingTreatmentRupture of Anterior Cruciate Ligament / Tear of Anterior Cruciate Ligament1

Pharmacoeconomics

Manufacturers
  • Solvay pharmaceuticals
  • Eastman kodak co
  • Hospira inc
  • Novocol pharmaceutical inc
  • Graham chemical co
  • International medication system
  • Watson laboratories inc
  • App pharmaceuticals llc
  • Dentsply pharmaceutical
  • Deproco inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionSubcutaneous30 mg/mL
LiquidEpidural; Intracaudal20 mg
SolutionEpidural; Intracaudal1 %
SolutionInfiltration1 %
SolutionEpidural; Intracaudal20 mg
SolutionInfiltration
SolutionInfiltration30 mg
LiquidEpidural; Intracaudal10 mg
LiquidIntraspinal20 mg
LiquidEpidural; Intracaudal1 %
LiquidInfiltration1 %
Injection, solutionSubcutaneous
SolutionSubcutaneous30 mg
Kit
Injection, solutionDental; Infiltration30 mg/mL
Injection, solutionInfiltration10 mg/mL
Injection, solutionInfiltration20 mg/mL
Injection, solutionEpidural; Infiltration10 mg/mL
Injection, solutionEpidural; Infiltration15 mg/mL
Injection, solutionEpidural; Infiltration20 mg/mL
LiquidInfiltration
LiquidInfiltration30 mg
Prices
Unit descriptionCostUnit
Mepivacaine hcl powder318.33USD g
Mepivacaine hcl 3% cartridge0.46USD ml
Carbocaine 1% vial0.26USD ml
Polocaine 1% vial0.25USD ml
Polocaine 2% vial0.24USD ml
Carbocaine 2% vial0.19USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)150.5 °CPhysProp
water solubility7000 mg/L (at 23 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.95HANSCH,C ET AL. (1995)
logS-1.55ADME Research, USCD
pKa7.7SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.621 mg/mLALOGPS
logP2.16ALOGPS
logP3.19ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)13.62ChemAxon
pKa (Strongest Basic)7.25ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.34 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity76.32 m3·mol-1ChemAxon
Polarizability28.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9568
Blood Brain Barrier+0.9749
Caco-2 permeable+0.6836
P-glycoprotein substrateSubstrate0.7866
P-glycoprotein inhibitor IInhibitor0.6872
P-glycoprotein inhibitor IINon-inhibitor0.8665
Renal organic cation transporterNon-inhibitor0.5878
CYP450 2C9 substrateNon-substrate0.7853
CYP450 2D6 substrateSubstrate0.7423
CYP450 3A4 substrateSubstrate0.7726
CYP450 1A2 substrateNon-inhibitor0.7996
CYP450 2C9 inhibitorNon-inhibitor0.933
CYP450 2D6 inhibitorInhibitor0.6146
CYP450 2C19 inhibitorNon-inhibitor0.9387
CYP450 3A4 inhibitorNon-inhibitor0.5395
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7497
Ames testNon AMES toxic0.8252
CarcinogenicityNon-carcinogens0.9333
BiodegradationNot ready biodegradable0.939
Rat acute toxicity1.7237 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.908
hERG inhibition (predictor II)Inhibitor0.6936
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.1 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0002-9000000000-6a3d80d214452a24ab62
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9040000000-3c0a89a13f39484eef97
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9000000000-9073826aa2631981fe72
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9000000000-9b273b91b5148ef6a8fa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9000000000-d541d397ca20f2f1a799
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-9000000000-eda45d03ea77058a8429
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-006t-9000000000-f42a147676c3c718e38f

Taxonomy

Description
This compound belongs to the class of organic compounds known as piperidinecarboxamides. These are compounds containing a piperidine ring substituted with a carboxamide functional group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Piperidinecarboxylic acids and derivatives
Direct Parent
Piperidinecarboxamides
Alternative Parents
m-Xylenes / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
Substituents
2-piperidinecarboxamide / Piperidinecarboxamide / M-xylene / Xylene / Monocyclic benzene moiety / Benzenoid / Tertiary aliphatic amine / Tertiary amine / Carboximidic acid / Carboximidic acid derivative
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
piperidinecarboxamide (CHEBI:6759)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
Gene Name
SCN10A
Uniprot ID
Q9Y5Y9
Uniprot Name
Sodium channel protein type 10 subunit alpha
Molecular Weight
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Leffler A, Reckzeh J, Nau C: Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol. 2010 Mar 25;630(1-3):19-28. doi: 10.1016/j.ejphar.2009.12.027. Epub 2010 Jan 4. [PubMed:20044988]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18